GHO Capital Partners acquires Genesis Research
London-based global healthcare investor GHO Capital Partners has acquired Genesis Research, a provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services.
Founded in 2009 and headquartered in Hoboken, New Jersey, Genesis services companies across the life sciences industry. It optimises drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilisation of integrated real-world data. The company has more than 120 employees in the US and UK.
Genesis has appointed David Miller as chairman, undertaking the role next year.
The partners at GHO Capital, stated: “The investment in Genesis follows years of work internally to identify market-leading platforms with ambitious management teams in RWE and HEOR. Recognising the rapid growth and macro tailwinds driving the sector, we are delighted to back a leader in this space. With our investment and specialist expertise, we look forward to supporting the shared ambition for Genesis to become a global leader in RWE and HEOR.”
Frank A Corvino, chief executive of Genesis Research, said: “We are extremely excited by this partnership and the opportunity to pursue our strategic priorities as well as scale our holistic, cross-functional engagement. GHO is a strong partner with healthcare expertise to accelerate our growth and expand our global footprint, which will in turn strengthen the capabilities across the sector leading to better healthcare outcomes. We’d also like to thank our first equity partner, Rallyday, for supporting our inspired vision.”
Ropes & Gray was legal advisor to GHO, CIL was commercial advisor, Alvarez and Marsal was financial advisor, Deloitte was tax advisor and CRS was insurance advisor.
Berg Hill Greenleaf Ruscitti was legal advisor to Genesis Research; Piper Sandler Companies was exclusive corporate finance advisor and RSM Global was tax advisor.